Download PDF
Semin Thromb Hemost 2012; 38(02): 185-199
DOI: 10.1055/s-0032-1301416
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Atherothrombosis in von Willebrand Disease: An Analysis of the Literature and Implications for Clinical Management

Massimo Franchini
1   Immunohematology and Transfusion Medicine, ‘Carlo Poma’ Hospital, Mantova, Italy
,
Antonio Coppola
2   Regional Reference Center for Coagulation Disorders, Federico II University Hospital, Naples, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
05 March 2012 (online)

    Permissions and Reprints

Abstract

In spite of coagulation impairment, people with congenital bleeding disorders can still develop atherosclerosis and its thrombotic complications. This issue has been particularly addressed in recent years as an increasing number of such patients now reach an elderly age and have to confront age-related comorbidities, including cardiovascular diseases, and as a consequence, challenges concerning the management of concomitant bleeding and atherothrombotic risk. Von Willebrand disease (VWD), caused by quantitative and/or functional defects of von Willebrand factor (VWF), is the most common congenital bleeding disorder, with an estimated prevalence in the general population of 1 to 2%, although clinically significant VWD is much less common. Despite the high population impact of VWD and increasing knowledge of the pathophysiological role of VWF in atherothrombosis, data concerning atherosclerosis and its vascular complications in VWD patients are rather limited, and even more scarce when clinical management is considered. The relevance of this association is certainly underestimated and, possibly, contributes to bleeding complications observed in patients on antithrombotic treatment or undergoing invasive cardiovascular procedures. This review will analyze the available literature data and discuss the implications for management of VWD patients with atherothrombosis, in the light of the information of bleeding risk in the general population and of recent, growing data from hemophilia patients.

Keywords

atherosclerosis - acute coronary syndrome - arterial thrombosis - cardiovascular disease - percutaneous coronary intervention - von Willebrand disease - von Willebrand factor
 

  • References

  • 1 Franchini M. Thrombotic complications in patients with hereditary bleeding disorders. Thromb Haemost 2004; 92 (2) 298-304
    PubMedGoogle Scholar
  • 2 Girolami A, Ruzzon E, Fabris F, Varvarikis C, Sartori R, Girolami B. Myocardial infarction and other arterial occlusions in hemophilia A patients. A cardiological evaluation of all 42 cases reported in the literature. Acta Haematol 2006; 116 (2) 120-125
    CrossrefPubMedGoogle Scholar
  • 3 Girolami A, Tezza F, Scapin M, Vettore S, Casonato A. Arterial and venous thrombosis in patients with von Willebrand’s disease: a critical review of the literature. J Thromb Thrombolysis 2006; 21 (2) 175-178
    CrossrefPubMedGoogle Scholar
  • 4 Tuinenburg A, Mauser-Bunschoten EP, Verhaar MC, Biesma DH, Schutgens REG. Cardiovascular disease in patients with hemophilia. J Thromb Haemost 2009; 7 (2) 247-254
    CrossrefPubMedGoogle Scholar
  • 5 Mannucci PM, Schutgens REG, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with hemophilia. Blood 2009; 114 (26) 5256-5263
    CrossrefPubMedGoogle Scholar
  • 6 Biere-Rafi S, Zwiers M, Peters M , et al. The effect of haemophilia and von Willebrand disease on arterial thrombosis: a systematic review. Neth J Med 2010; 68 (5) 207-214
    PubMedGoogle Scholar
  • 7 Coppola A, Tagliaferri A, Franchini M. The management of cardiovascular diseases in patients with hemophilia. Semin Thromb Hemost 2010; 36 (1) 91-102
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Schutgens REG, Tuinenburg A, Roosendaal G, Guyomi SH, Mauser-Bunschoten EP. Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline. Haemophilia 2009; 15 (4) 952-958
    CrossrefPubMedGoogle Scholar
  • 9 Sadler JE, Budde U, Eikenboom JC , et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4 (10) 2103-2114
    CrossrefPubMedGoogle Scholar
  • 10 Schneppenheim R, Budde U. von Willebrand factor: the complex molecular genetics of a multidomain and multifunctional protein. J Thromb Haemost 2011; 9 (Suppl 1) 209-215
    PubMedGoogle Scholar
  • 11 Mayadas T, Wagner DD, Simpson PJ. von Willebrand factor biosynthesis and partitioning between constitutive and regulated pathways of secretion after thrombin stimulation. Blood 1989; 73 (3) 706-711
    PubMedGoogle Scholar
  • 12 Dong JF, Moake JL, Nolasco L , et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100 (12) 4033-4039
    CrossrefPubMedGoogle Scholar
  • 13 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987; 69 (2) 454-459
    PubMedGoogle Scholar
  • 14 Federici AB. Diagnosis of inherited von Willebrand disease: a clinical perspective. Semin Thromb Hemost 2006; 32 (6) 555-565
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Franchini M, Mannucci PM. Von Willebrand factor: another janus-faced hemostasis protein. Semin Thromb Hemost 2008; 34 (7) 663-669
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 van Schie MC, van Loon JE, de Maat MP, Leebeek FW. Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. J Thromb Haemost 2011; 9 (5) 899-908
    CrossrefPubMedGoogle Scholar
  • 17 Ruggeri ZM. Von Willebrand factor. Curr Opin Hematol 2003; 10 (2) 142-149
    CrossrefPubMedGoogle Scholar
  • 18 Goto S, Ikeda Y, Saldívar E, Ruggeri ZM. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest 1998; 101 (2) 479-486
    CrossrefPubMedGoogle Scholar
  • 19 Goto S, Sakai H, Goto M , et al. Enhanced shear-induced platelet aggregation in acute myocardial infarction. Circulation 1999; 99 (5) 608-613
    CrossrefPubMedGoogle Scholar
  • 20 Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96 (4) 1102-1108
    CrossrefPubMedGoogle Scholar
  • 21 Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17 (11) 3321-3325
    CrossrefPubMedGoogle Scholar
  • 22 Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC ; European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332 (10) 635-641
    CrossrefPubMedGoogle Scholar
  • 23 Jager A, van Hinsbergh VW, Kostense PJ , et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19 (12) 3071-3078
    CrossrefPubMedGoogle Scholar
  • 24 Whincup PH, Danesh J, Walker M , et al. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 2002; 23 (22) 1764-1770
    CrossrefPubMedGoogle Scholar
  • 25 Morange PE, Simon C, Alessi MC , et al; PRIME Study Group. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004; 109 (11) 1343-1348
    CrossrefPubMedGoogle Scholar
  • 26 van der Meer IM, Brouwers GJ, Bulk S , et al. Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study. Br J Haematol 2004; 124 (3) 343-347
    CrossrefPubMedGoogle Scholar
  • 27 Folsom AR, Rosamond WD, Shahar E , et al; The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Prospective study of markers of hemostatic function with risk of ischemic stroke. Circulation 1999; 100 (7) 736-742
    CrossrefPubMedGoogle Scholar
  • 28 Wieberdink RG, van Schie MC, Koudstaal PJ , et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke 2010; 41 (10) 2151-2156
    CrossrefPubMedGoogle Scholar
  • 29 Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008; 6 (1) 62-69
    PubMedGoogle Scholar
  • 30 Miura M, Kaikita K, Matsukawa M , et al. Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease. Thromb Haemost 2010; 103 (3) 623-629
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Bongers TN, de Bruijne EL, Dippel DW , et al. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis 2009; 207 (1) 250-254
    CrossrefPubMedGoogle Scholar
  • 32 van Schie MC, de Maat MP, Isaacs A , et al. Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular disease. Blood 2011; 117 (4) 1393-1399
    CrossrefPubMedGoogle Scholar
  • 33 Mannucci PM. Platelet/von Willebrand factor inhibitors to the rescue of ischemic stroke. Arterioscler Thromb Vasc Biol 2010; 30 (10) 1882-1884
    CrossrefPubMedGoogle Scholar
  • 34 Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407 (6801) 258-264
    CrossrefPubMedGoogle Scholar
  • 35 Major CD, Santulli RJ, Derian CK, Andrade-Gordon P. Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice. Arterioscler Thromb Vasc Biol 2003; 23 (6) 931-939
    CrossrefPubMedGoogle Scholar
  • 36 Coughlin SR, Camerer E. PARticipation in inflammation. J Clin Invest 2003; 111 (1) 25-27
    PubMedGoogle Scholar
  • 37 Fuster V, Fass DN, Kaye MP, Josa M, Zinsmeister AR, Bowie EJ. Arteriosclerosis in normal and von Willebrand pigs: long-term prospective study and aortic transplantation study. Circ Res 1982; 51 (5) 587-593
    CrossrefPubMedGoogle Scholar
  • 38 Griggs TR, Reddick RL, Sultzer D, Brinkhous KM. Susceptibility to atherosclerosis in aortas and coronary arteries of swine with von Willebrand’s disease. Am J Pathol 1981; 102 (2) 137-145
    PubMedGoogle Scholar
  • 39 Badimon L, Steele P, Badimon JJ, Bowie EJ, Fuster V. Aortic atherosclerosis in pigs with heterozygous von Willebrand disease. Comparison with homozygous von Willebrand and normal pigs. Arteriosclerosis 1985; 5 (4) 366-370
    CrossrefPubMedGoogle Scholar
  • 40 Methia N, André P, Denis CV, Economopoulos M, Wagner DD. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood 2001; 98 (5) 1424-1428
    CrossrefPubMedGoogle Scholar
  • 41 Nichols TC, Bellinger DA, Tate DA , et al. von Willebrand factor and occlusive arterial thrombosis. A study in normal and von Willebrand’s disease pigs with diet-induced hypercholesterolemia and atherosclerosis. Arteriosclerosis 1990; 10 (3) 449-461
    CrossrefPubMedGoogle Scholar
  • 42 Kleinschnitz C, De Meyer SF, Schwarz T , et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood 2009; 113 (15) 3600-3603
    CrossrefPubMedGoogle Scholar
  • 43 De Meyer SF, Schwartz T, Deckmyn H , et al. Binding of von Willebrand factor to collagen and glycoprotein Ibalpha but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice-brief report. Arterioscler Thromb Vasc Biol 2010; 30 (10) 1949-1951
    CrossrefPubMedGoogle Scholar
  • 44 Silwer J, Cronberg S, Nilsson IM. Occurrence of arteriosclerosis in von Willebrand’s disease. Acta Med Scand 1966; 180 (4) 475-484
    PubMedGoogle Scholar
  • 45 Kernoff LM, Rose AG, Hughes J, Jacobs P. Autopsy findings in an elderly man suffering from severe von Willebrand’s disease. Thromb Haemost 1981; 46 (4) 714-716
    PubMedGoogle Scholar
  • 46 Federici AB, Mannucci PM, Fogato E, Ghidoni P, Matturri L. Autopsy findings in three patients with von Willebrand disease type IIB and type III: presence of atherosclerotic lesions without occlusive arterial thrombi. Thromb Haemost 1993; 70 (5) 758-761
    PubMedGoogle Scholar
  • 47 Bilora F, Dei Rossi C, Girolami B , et al. Do hemophilia A and von Willebrand disease protect against carotid atherosclerosis? A comparative study between coagulopathics and normal subjects by means of carotid echo-color Doppler scan. Clin Appl Thromb Hemost 1999; 5 (4) 232-235
    CrossrefPubMedGoogle Scholar
  • 48 Srámek A, Reiber JHC, Gerrits WBJ, Rosendaal FR. Decreased coagulability has no clinically relevant effect on atherogenesis: observations in individuals with a hereditary bleeding tendency. Circulation 2001; 104 (7) 762-767
    CrossrefPubMedGoogle Scholar
  • 49 Bilora F, Boccioletti V, Zanon E, Petrobelli F, Girolami A. Hemophilia A, von Willebrand disease, and atherosclerosis of abdominal aorta and leg arteries: factor VIII and von Willebrand factor defects appear to protect abdominal aorta and leg arteries from atherosclerosis. Clin Appl Thromb Hemost 2001; 7 (4) 311-313
    CrossrefPubMedGoogle Scholar
  • 50 Srámek A, Bucciarelli P, Federici AB , et al. Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation 2004; 109 (6) 740-744
    CrossrefPubMedGoogle Scholar
  • 51 Bilora F, Zanon E, Casonato A , et al. Type IIb von Willebrand disease: role of qualitative defects in atherosclerosis and endothelial dysfunction. Clin Appl Thromb Hemost 2007; 13 (4) 384-390
    CrossrefPubMedGoogle Scholar
  • 52 Mannucci PM. Treatment of von Willebrand’s disease. N Engl J Med 2004; 351 (7) 683-694
    CrossrefPubMedGoogle Scholar
  • 53 Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88 (3) 378-379
    Article in Thieme ConnectPubMedGoogle Scholar
  • 54 Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand’s disease. Thromb Haemost 2002; 88 (3) 387-388
    PubMedGoogle Scholar
  • 55 Moss RA, Mena RR, Morin RJ. Atherosclerosis and a coronary artery bypass operation in a woman with von Willebrand disease. West J Med 1980; 133 (6) 515-517
    PubMedGoogle Scholar
  • 56 Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. Medicine (Baltimore) 1983; 62 (4) 248-255
    PubMedGoogle Scholar
  • 57 Dulhoste MN, Bonnet J, Vergnes C, Choussat A, Bricaud H. [von Willebrand’s disease and coronary atherosclerosis. Apropos of 3 cases]. Arch Mal Coeur Vaiss 1989; 82 (11) 1875-1878
    PubMedGoogle Scholar
  • 58 Slaughter TF, Mody EA, Oldham Jr HN , et al. Management of a patient with type IIC von Willebrand’s disease during coronary artery bypass graft surgery. Anesthesiology 1993; 78 (1) 195-197
    CrossrefPubMedGoogle Scholar
  • 59 Wong CB, Schreiber TL. Acute myocardial infarction in a patient with von Willebrand disease. Cathet Cardiovasc Diagn 1996; 38 (3) 287-288
    CrossrefPubMedGoogle Scholar
  • 60 Fragasso G, Camba L, Pizzetti G, Pagnotta P, Chierchia SL. Successful thrombolysis for acute myocardial infarction in Type I von Willebrand’s disease (vWD). Am J Hematol 1998; 57 (2) 180
    PubMedGoogle Scholar
  • 61 James PR, de Belder AJ, Kenny MW. Successful percutaneous transluminal coronary angioplasty for acute myocardial infarction in von Willebrand’s disease. Haemophilia 2002; 8 (6) 826-827
    CrossrefPubMedGoogle Scholar
  • 62 Arjomand H, Aquilina P, McCormick D. Acute myocardial infarction in a patient with von Willebrand disease: pathogenetic dilemmas and therapeutic challenges. J Invasive Cardiol 2002; 14 (10) 615-618
    PubMedGoogle Scholar
  • 63 Franchini M, Veneri D. Are only haemophiliacs protected against ischemic heart disease?. Thromb Haemost 2004; 92 (6) 1455-1456
    PubMedGoogle Scholar
  • 64 Grainge C, Nokes T. Cerebral arterial thrombosis in a young woman following vasopressin for von Willebrand’s disease. Thromb Haemost 2005; 93 (2) 380
    PubMedGoogle Scholar
  • 65 Macdonald J, Srinivasan M, More R. Percutaneous coronary intervention in a patient with von Willebrand’s disease presenting with an acute coronary syndrome. J Invasive Cardiol 2006; 18 (4) 174-177
    PubMedGoogle Scholar
  • 66 Gerling V, Lahpor JR, Buhre W. Peri-operative management of an adult patient with type 2N von Willebrand’s disease scheduled for coronary artery bypass graft. Anaesthesia 2007; 62 (4) 405-408
    CrossrefPubMedGoogle Scholar
  • 67 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329) 71-86
    CrossrefPubMedGoogle Scholar
  • 68 Patrono C, Baigent C, Hirsh J, Roth G ; American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl) 199S-233S
    CrossrefPubMedGoogle Scholar
  • 69 Harrington RA, Becker RC, Cannon CP , et al; American College of Chest Physicians. Antithrombotic therapy for Non-ST-Segment Elevation Acute coronary syndromes. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl) 670S-707S
    CrossrefPubMedGoogle Scholar
  • 70 Goodman SG, Menon V, Cannon CP , et al; American College of Chest Physicians. Acute ST-Segment Elevation Myocardial Infarction. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl) 708S-775S
    CrossrefPubMedGoogle Scholar
  • 71 Moscucci M, Fox KA, Cannon CP , et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24 (20) 1815-1823
    CrossrefPubMedGoogle Scholar
  • 72 Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344 (17) 1286-1292
    CrossrefPubMedGoogle Scholar
  • 73 Merlini PA, Rossi M, Menozzi A , et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004; 109 (18) 2203-2206
    CrossrefPubMedGoogle Scholar
  • 74 Ky B, Kasner M, Carver JR. von Willebrand disease and coronary artery disease: a contemporary review. J Invasive Cardiol 2006; 18 (4) 178-182
    PubMedGoogle Scholar
  • 75 Greenland P, Alpert JS, Beller GA , et al; 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010; 122 (25) 2748-2764
    CrossrefPubMedGoogle Scholar
  • 76 D’Agostino Sr RB, Vasan RS, Pencina MJ , et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117 (6) 743-753
    CrossrefPubMedGoogle Scholar
  • 77 Conroy RM, Pyörälä K, Fitzgerald AP , et al; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24 (11) 987-1003
    CrossrefPubMedGoogle Scholar
  • 78 Biere-Rafi S, Baarslag MA, Peters M , et al. Cardiovascular risk assessment in haemophilia patients. Thromb Haemost 2011; 105 (2) 274-278
    PubMedGoogle Scholar
  • 79 Shaw SM, Fildes JE, Yonan N, Williams SG. Pleiotropic effects and cholesterol-lowering therapy. Cardiology 2009; 112 (1) 4-12
    CrossrefPubMedGoogle Scholar
  • 80 Yarnell JW, Sweetnam PM, Rumley A, Lowe GD. Lifestyle and hemostatic risk factors for ischemic heart disease : the Caerphilly Study. Arterioscler Thromb Vasc Biol 2000; 20 (1) 271-279
    CrossrefPubMedGoogle Scholar
  • 81 Barbui T, Rodeghiero F, Dini E. The aspirin tolerance test in von Willebrand’s disease. Thromb Haemost 1977; 38 (2) 510-513
    PubMedGoogle Scholar
  • 82 Miesbach W, Berntorp E. When von Willebrand disease comes into age - a matter of change?. Eur J Haematol 2011; 86 (6) 496-501
    CrossrefPubMedGoogle Scholar
  • 83 Federici AB. Prophylaxis of bleeding episodes in patients with von Willebrand’s disease. Blood Transfus 2008; 6 (Suppl 2) s26-s32
    PubMedGoogle Scholar
  • 84 Savonitto S, Ardissino D, Granger CB , et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999; 281 (8) 707-713
    CrossrefPubMedGoogle Scholar
  • 85 Kinnaird T, Anderson R, Hill J, Thomas M. Bleeding during percutaneous intervention: tailoring the approach to minimise risk. Heart 2009; 95 (1) 15-19
    CrossrefPubMedGoogle Scholar
  • 86 Cantor WJ, Puley G, Natarajan MK , et al. Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction—the RADIAL-AMI pilot randomized trial. Am Heart J 2005; 150 (3) 543-549
    CrossrefPubMedGoogle Scholar
  • 87 Koreny M, Riedmüller E, Nikfardjam M, Siostrzonek P, Müllner M. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. JAMA 2004; 291 (3) 350-357
    CrossrefPubMedGoogle Scholar
  • 88 Mannucci PM, Franchini M, Castaman G, Federici AB ; Italian Association of Hemophilia Centers. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus 2009; 7 (2) 117-126
    PubMedGoogle Scholar
  • 89 Budde U, Metzner HJ, Müller HG. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Hemost 2006; 32 (6) 626-635
    Article in Thieme ConnectPubMedGoogle Scholar
  • 90 Antman EM, Cohen M, Radley D , et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100 (15) 1602-1608
    CrossrefPubMedGoogle Scholar
  • 91 Ferguson JJ, Califf RM, Antman EM , et al; SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292 (1) 45-54
    CrossrefPubMedGoogle Scholar
  • 92 Karthikeyan G, Mehta SR, Eikelboom JW. Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6. Expert Rev Cardiovasc Ther 2009; 7 (3) 241-249
    CrossrefPubMedGoogle Scholar
  • 93 Maroo A, Lincoff AM. Bivalirudin in PCI: an overview of the REPLACE-2 trial. Semin Thromb Hemost 2004; 30 (3) 329-336
    Article in Thieme ConnectPubMedGoogle Scholar
  • 94 Harker LA, Boissel JP, Pilgrim AJ, Gent M. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf 1999; 21 (4) 325-335
    CrossrefPubMedGoogle Scholar
  • 95 Iakovou I, Schmidt T, Bonizzoni E , et al. Incidence, prediction and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 4;293 (17) 2126-2130
    PubMedGoogle Scholar
  • 96 Banerjee S, Varghese C, Samuel J , et al. Comparison of the impact of short (<1 year) and long-term (> or = 1 year) clopidogrel use following percutaneous coronary intervention on mortality. Am J Cardiol 2008; 102 (9) 1159-1162
    CrossrefPubMedGoogle Scholar
  • 97 Kwa AT, Rogers JH. Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy. J Interv Cardiol 2008; 21 (2) 107-117
    CrossrefPubMedGoogle Scholar
  • 98 Franchini M, Mannucci PM. New antiplatelet agents: why they are needed. Eur J Intern Med 2009; 20 (8) 733-738
    CrossrefPubMedGoogle Scholar
  • 99 Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90 (1) 583-612
    CrossrefPubMedGoogle Scholar
  • 100 Italian Society of Invasive Cardiology. Available at: www.gise.it . Accessed on August 19, 2011
    PubMedGoogle Scholar
  • 101 Tosetto A, Castaman G, Plug I, Rodeghiero F, Eikenboom J. Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. J Thromb Haemost 2011; 9 (6) 1143-1148
    CrossrefPubMedGoogle Scholar